Cala Presents Multiple Clinical Studies Demonstrating Impact of Transcutaneous Afferent Patterned Stimulation (TAPS) Therapy in Essential Tremor (ET) Patients at the American Academy of Neurology (AAN)
Summary
SAN MATEO, Calif., April 7, 2025 /PRNewswire/ -- Cala, the bioelectronic medicine leader, who recently raised an oversubscribed growth financing round and was recognized on Fast Companys annual top 10 list of the Most Innovative Medical Device Companies in 2025, announced at the American Academy of Neurology (AAN) meeting in San Diego, CA, the results from multiple clinical studies further expanding the robust body of evidence for Cala TAPS Therapy. https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-002253.htmlA mechanism of action study used direct brain recordings to show TAPS modulated neural activity in the ventral intermediate (VIM) nucleus of the thalamus. https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-003933.htmlA 12-month prospective study of Cala TAPS Therapy demonstrated significant tremor relief and reduced ET-related healthcare costs in patients. With the only FDA cleared wearable neuromodulation system commercially available for tremor relief in ET and PD patients, Cala continues to raise the bar with advancements in technology and clinical evidence. Cala will continue to advocate on behalf of patients with ET to secure additional coverage and reimbursement in Medicare Advantage and commercial payor plans.About Cala\xaeCala Health is a bioelectronic medicine company transforming the standard of care for chronic disease.